Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy
between this translated document and the Japanese original, the original shall prevail.

August 3, 2022

NEWS RELEASE
Company name:
Listing:
Securities code:
URL:
Representative:
Contact:
Telephone:

TSUMURA & CO.
TSE Prime Market
4540
https://www.tsumura.co.jp
Terukazu Kato, President, Representative Director and CEO
Ritsuko Inukai, Head of Corporate Communications Dept.
+81-3-6361-7100

Tsumura Announces Establishment ofPINGAN TSUMURA TRADITIONAL CHINESE MEDICINE TECHNOLOGY CO., LTD.
Tsumura & Co. (Headquarters: Tokyo, Japan; President Representative Director and CEO: Terukazu Kato; hereafter,“Tsumura”) announces that, at a meeting of its Board of Directors held on August 3, 2022, Tsumura received a reporton the completion of the establishment of a new company by Ping An Tsumura Inc. (Headquarters: Shanghai, China),
which is a joint venture between Tsumura China Inc. (Headquarters: Shanghai, China), a wholly owned subsidiary,of Tsumura, and China Ping An Life Insurance Co., Ltd. (Headquarters: Guangdong, China). Details are as follows.
1. Aim of establishment of the new company
As a research platform in the Group’s China business, the new company will have the function of formulating quality
standards covering the entire supply chain from the seeding of crude drugs to final products, researching theproduction and quality of crude drugs, and researching the quality of traditional Chinese medicinal products, and theaim of its establishment is to support the development of a crude drug platform/crude drug product platform. The
new company will promote the development of quality standards for crude drugs and crude drug products and seek
their widespread use in China, thereby earning trust in China and endeavoring to enhance corporate value by
improving brand recognition.
The new company will lease the facilities of SHENZHEN TSUMURA MEDICINE CO.,LTD., a wholly owned
subsidiary of Tsumura, and launch some research services from October this year. A building specifically for the newcompany is due to be completed in 2024.
2. Outline of the company to be established(1) Name of company
PINGAN TSUMURA TRADITIONAL CHINESE MEDICINE TECHNOLOGYCO., LTD.
(2) Location
Shenzhen, Guangdong, China(3) Representative
Liu Yude, Chairman(4) Business description
Analysis and research business focusing on traditional Chinese medicine(5) Capital
150 million RMB(6) Date of foundation
June 29, 2022
(7) Investment ratio
Ping An Tsumura Inc.: 100%

3. Outline of Ping An Tsumura Inc.
(1) Name of company
Ping An Tsumura Inc.
(2) Location
Shanghai, China(3) Representative
Tung Hoi, Chairman(4) Business description
Business related to strengthening the crude drug procurement structure, business
related to analysis and research focusing on traditional Chinese medicines, andbusiness related to traditional Chinese medicines, health food and healthcare-related
daily necessities and other operations and markets, etc.
(5) Capital
2,000 million RMB(6) Date of foundation
June 8, 2018(7) Investment ratio
Tsumura China Inc.: 56%
China Ping An Life Insurance Co., Ltd.: 44%
4. Future outlook
The effect of the establishment of the new company on the consolidated results of Tsumura in the fiscal year ending
March 31, 2023 will be minor and insignificant.